Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ASH 2025

6 - 8 Dec 2025

Orange County Convention Center, Orlando, United States of America

ASH 2025: Pirtobrutinib outperforms bendamustine plus rituximab for previously untreated CLL/SLL

ASH 2025: Pirtobrutinib outperforms bendamustine plus rituximab for previously untreated CLL/SLL

$ASH 2025: Tec-Dara combination offers substantial improvement over standard second-line therapies for relapsed or refractory multiple myeloma$

ASH 2025: Tec-Dara combination offers substantial improvement over standard second-line therapies for relapsed or...

ASH 2025: Developed antibody boosts immune response against blood cancers and solid cancers

ASH 2025: Developed antibody boosts immune response against blood cancers and solid cancers

ASH 2025: Home-based monitoring could transform care for patients receiving T-cell redirecting therapies

ASH 2025: Home-based monitoring could transform care for patients receiving T-cell redirecting therapies

ASH 2025: Study connects Agent Orange exposure to earlier and more severe cases of myelodysplastic syndrome

ASH 2025: Study connects Agent Orange exposure to earlier and more severe cases of myelodysplastic syndrome

ASH 2025: New findings support a chemo-free approach for treating Ph+ ALL

ASH 2025: New findings support a chemo-free approach for treating Ph+ ALL

ASH 2025: ‘Ready-made’ T-cell gene therapy tackles ‘incurable’ T-cell leukaemia

ASH 2025: ‘Ready-made’ T-cell gene therapy tackles ‘incurable’ T-cell leukaemia

ASH 2025: New data highlights promise of pivekimab sunirine in two aggressive blood cancers

ASH 2025: New data highlights promise of pivekimab sunirine in two aggressive blood cancers 

ASH 2025: New combination approach aims to make CAR T more durable in lymphoma

ASH 2025: New combination approach aims to make CAR T more durable in lymphoma

ASH 2025: Adding epcoritamab to standard second-line therapy improves follicular lymphoma outcomes

ASH 2025: Adding epcoritamab to standard second-line therapy improves follicular lymphoma outcomes

ASH 2025: Non-covalent btki pirtobrutinib shows promise as frontline therapy for CLL/SLL

ASH 2025: Non-covalent btki pirtobrutinib shows promise as frontline therapy for CLL/SLL

ASH 2025: AI uncovers how DNA architecture failures trigger blood cancer

ASH 2025: AI uncovers how DNA architecture failures trigger blood cancer

ASH 2025: Measurable residual disease shows strong potential as an early indicator of survival in acute myeloid leukaemia

ASH 2025: Measurable residual disease shows strong potential as an early indicator of survival in acute myeloid...

ASH 2025: Study suggests that a virtual programme focusing on diet and exercise can help reduce side effects of lymphoma treatment

ASH 2025: Study suggests that a virtual programme focusing on diet and exercise can help reduce side effects of...

ASH 2025: CAR T cell therapy shows promising phase II trial results in multiple myeloma

ASH 2025: CAR T cell therapy shows promising phase II trial results in multiple myeloma

ASH 2025: Protective regimen allows successful stem cell transplant even without close genetic match between donor and recipient

ASH 2025: Protective regimen allows successful stem cell transplant even without close genetic match between donor...

ASH 2025: Antibody therapy eradicates traces of multiple myeloma in preliminary trial

ASH 2025: Antibody therapy eradicates traces of multiple myeloma in preliminary trial

ASH 2025: Azacitidine–venetoclax combination outperforms standard care in acute myeloid leukaemia patients eligible for intensive chemotherapy

ASH 2025: Azacitidine–venetoclax combination outperforms standard care in acute myeloid leukaemia patients...

ASH 2025: Delayed toxicities after CAR T cell therapy for multiple myeloma are connected and potentially preventable

ASH 2025: Delayed toxicities after CAR T cell therapy for multiple myeloma are connected and potentially...

ASH 2025: Researchers identify CD40 as potential biomarker for a type of nodal T cell lymphoma

ASH 2025: Researchers identify CD40 as potential biomarker for a type of nodal T cell lymphoma

ASH 2025: Milder chemo works for rare, aggressive lymphoma

ASH 2025: Milder chemo works for rare, aggressive lymphoma

ASH 2025: Chemo and radiation are comparable as pre-transplant conditioning for B-acute lymphoblastic leukaemia with no measurable residual disease

ASH 2025: Chemo and radiation are comparable as pre-transplant conditioning for B-acute lymphoblastic leukaemia...

ASH 2025: Continuous and fixed-duration treatments result in similar outcomes for CLL

ASH 2025: Continuous and fixed-duration treatments result in similar outcomes for CLL

More from ecancer